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Fructose has recently been the focus of much 
interest as a possible contributor to the current 
epidemic of metabolic diseases. What is fructose, 
and why is it implicated in metabolic disease?
Fructose  is  a  hexose  with  the  same  chemical  formula, 
C6H12O6, as glucose. These two sweet-tasting molecules 
differ structurally, however, as fructose has a keto-group 
on the first carbon while glucose presents an aldehyde 
group on the second carbon. Free fructose, together with 
free glucose, is present in small amounts in fruits and 
honey. The main part of today’s dietary fructose intake 
comes  from  sucrose,  a  disaccharide  composed  of  one 
molecule  of  glucose  linked  to  a  molecule  of  fructose 
through an alpha 1-4 glycoside bond.
The link with metabolic disease is partly circumstantial. 
Fructose consumption has been low throughout most of 
human history, but started to increase after the crusades, 
when  Europeans  became  acquainted  with  sucrose 
produced from sugar cane in Asia. It was at first a luxury 
product, but consumption rapidly increased in the 16th 
and  17th  centuries  when  sugar  became  more  widely 
available  as  a  consequence  of  colonial  trading.  Its 
consumption  was  boosted,  first  by  the  introduction  of 
new beverages – tea, coffee, and cocoa in the 17th to 18th 
centuries; and second with the production of chocolate 
bars, ice-creams, and sodas at the beginning of the 20th 
century.  Total  sugar  consumption  thus  increased  from 
less than 5 kg/person/year in the 1800s to about 40 kg at 
the turn of the 19th century, and about 70 kg/person/year 
in  2006.  In  short,  a  rapid  and  continuous  increase  in 
consumption  has  been  observed  from  1750  until  the 
present day.
In the 1960s, a novel food technology allowed the large-
scale, industrial conversion of glucose into fructose. As a 
result,  the  US  corn  industry  started  preparing  what  is 
now known as high fructose corn syrup (HFCS), that is, a 
concentrated  solution  of  corn-derived  glucose  and 
fructose  mixed  in  various  relative  proportions.  Mainly 
because  of  its  low  cost,  HFCS  consumption  replaced 
approximately one-third of the total sugar consumption 
in the USA between 1970 and 2000, paralleling to some 
extent  the  increasing  prevalence  of  obesity  during  this 
period. Consequently, HFCS has been a particular focus 
of  possible  blame  for  the  obesity  epidemic.  However, 
HFCS consumption has remained very low in other parts 
of the world where obesity has also increased, and the 
most commonly used form of HFCS contains about 55% 
fructose, 42% glucose , and 3% other sugars, and hence is 
associated with similar total fructose and glucose intakes 
as with sugar. Furthermore, sucrose is hydrolyzed in the 
gut  and  absorbed  into  the  blood  as  free  glucose  and 
fructose, so one would expect HFCS and sucrose to have 
the  same  metabolic  consequences.  In  short,  there  is 
currently  no  evidence  to  support  the  hypothesis  that 
HFCS  makes  a  significant  contribution  to  metabolic 
disease  independently  of  the  rise  in  total  fructose 
consumption.
So why the focus on fructose in particular?
Several reasons. First of all, fructose is not essential for 
any  physiological  function  that  we  know  of.  This  is  in 
contrast to glucose, which is used by all cells in the body 
to generate energy and constitutes the nearly exclusive 
energy fuel for the brain. As a consequence of this largely 
exclusive  reliance  on  glucose  for  brain  metabolism, 
intricate hormonal and neural mechanisms have evolved 
to maintain a constant level of glucose in the blood.
We do not need to eat sugar to maintain blood glucose 
levels,  however.  Until  relatively  recently,  our  dietary 
source  of  glucose  was  derived  from  complex 
carbohydrates,  principally  from  grains.  Grains  contain 
starch, which is a polymer of several thousands of glucose 
molecules linked together by alpha 1-4 glycosidic bonds, 
with  occasional  branching  points  due  to  alpha  1-6 
glycosidic bonds. Cooked starch can be readily digested 
by amylase produced by the salivary glands and pancreas, 
resulting in the formation of maltodextrins (small chains 
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or  triomaltose  in  the  gut  lumen  (Figure  1).  These 
compounds  are  subsequently  digested  into  glucose  by 
brush  border  enzymes  of  the  duodenum  and  jejunum. 
Ingestion  of  starchy  products  therefore  provides  a 
plentiful supply of glucose, which, upon absorption into 
the circulation, can be used as an energy source by most 
cells, or be stored as glycogen in the liver and in muscle.
With the exception of a limited amount of free glucose 
and fructose present in honey and fruits, grains and other 
starchy food have been the sole source of carbohydrate in 
the western diet for the major portion of man’s history. 
Sucrose is not only a non-essential dietary element, it has 
two undesirable consequences. First, because of its rapid 
digestion, it leads to surges in blood glucose that may 
place  some  stress  on  the  homeostatic  mechanisms 
mediated by insulin; and second, it introduces fructose, 
which  we  do  not  need  and  whose  metabolism,  when 
ingested  in  excessive  amounts,  imposes  an  important 
metabolic burden on the liver.
How do we metabolize fructose? Is it treated 
differently from glucose?
Yes it is. Glucose derived from fruits, sugar or digestion 
of starch is absorbed through the gut into the portal vein. 
A portion (15 to 30%) of glucose reaching the liver in this 
way  is  transported  into  hepatocytes  by  the  membrane 
transporter GLUT2. Once in the cell, glucose is converted 
into  glucose-6-phosphate  under  the  control  of  gluco-
kinase, then into fructose 1-6 diphosphate through the 
action of phosophofructose kinase and finally to triose-
phosphate and pyruvate. Pyruvate can then be decarboxylated 
to acetyl coenzyme A, and enter the tricarboxylic acid cycle 
for ATP production. Intracellular ATP and citrate exert a 
negative feedback on phosphofructokinase, so that hepatic 
glucose catabolism is tuned to the energy status of the 
Figure 1. Digestion and absorption of starch and sugar. Starch is a polymer of several thousand molecules of glucose, which is digested by the 
pancreatic enzyme alpha-amylase into maltose, isomaltose, maltotriose (not represented in the figure) and maltodextrins. At the level of the brush 
border of the intestinal mucosa, specific enzymes generate glucose from maltose (sucrase, maltase), isomaltose (isomaltase) and maltodextrins 
(glucoamylase). Glucose is then absorbed into the enterocyte by an apical co-transport with NaCl (Sodium-glucose-transporter-1, SGLT1) and 
transferred to the blood at the basolateral membrane through a facilitated transport mediated by GLUT2. Sucrose is cleaved into glucose and 
fructose by sucrase at the brush border. Fructose is transported into the enterocyte independently of Na by GLUT5, and due to the presence of 
fructose metabolizing, gluconeogenic and lipogenic enzymes, part of the absorbed fructose may be metabolized to lactate, glucose, and fatty 
acids within the enterocytes. Unmetabolized fructose is transferred to the blood at the basolateral membrane by GLUT2.
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Page 2 of 7liver cells, and insulin regulates glucokinase expression 
and the activity of key glycolytic enzymes. Thus, in liver 
cells,  as  in  other  cells  of  the  body,  the  breakdown  of 
glucose is matched to meet energy requirements.
By contrast, fructose metabolism is not tuned to energy 
needs. A limited amount of fructose may be metabolized 
within  the  gut  enterocytes,  but  for  the  most  part  it  is 
absorbed through the gut into the portal vein. As with 
glucose,  it  is  transported  into  hepatocytes  by  GLUT2. 
However, once inside the hepatocyte, it is very rapidly 
converted into fructose-1-phosphate under the action of 
fructokinase,  and  then  to  triose-phosphate  under  the 
action of aldolase B. These two enzymes act specifically 
on fructose and fructose-1-phosphate, respectively, and 
are regulated neither by insulin nor by the energy status 
of the cell. As a consequence most fructose in portal blood 
is rapidly converted into triose-phosphate in hepatocytes. 
This leads to 1) a high consumption rate of hepatic ATP 
for the initial phosphorylation of fructose, which can lead, 
when fructose intake is high, to transient ATP depletion, 
formation of AMP and degradation of adenosine to uric 
acid;  2)  an  overflow  of  triose-phosphates,  which  are 
secondarily  converted  into  lactate  or  glucose  to  be 
released into the circulation; 3) stimulation of glycogen 
synthesis;  and  4)  stimulation  of  the  synthesis  of  fatty 
acids from the carbons of fructose, through a metabolic 
pathway known as de novo lipogenesis (Figure 2).
Are there harmful consequences of these features 
of fructose metabolism?
At a high level of intake, yes, and one of these is increased 
cardiovascular  risk.  Paradoxically  this  in  part  came  to 
light because of a strong interest, in the 1980s, in the use 
of  pure  fructose  as  a  sweetener  for  type  2  diabetic 
patients. This was proposed on the grounds that fructose 
might be less harmful than sucrose or glucose because, 
unlike glucose, it causes little hyperglycemia after eating 
(postprandial  hyperglygemia),  and  is  metabolized 
independently  of  insulin.  Furthermore,  it  enhances 
energy expenditure compared to similar doses of glucose, 
which was thought to help prevent weight gain.
However,  many  short-term  studies  showed  that 
substituting  fructose  for  starch  in  the  diet  of  type  2 
diabetic  patients  was  associated  with  an  increase  in 
plasma  triglyceride  concentrations  (both  fasting  and 
postprandial), raising the possibility that any beneficial 
effect  on  glycemic  control  may  be  counterbalanced  by 
pro-atherogenic effects of hypertriglyceridemia.
If everyone’s liver cells, not just those of type 2 
diabetes patients, make triglycerides, couldn’t this 
also be a hazard for healthy people?
Yes. In healthy subjects, short-term overfeeding studies 
with  large  doses  of  fructose  (in  the  1.5  to  3  g/kg/day, 
corresponding  to  15  to  30%  total  energy  requirement) 
have  repeatedly  reported  an  increase  in  fasting  and 
postprandial  triglycerides,  mainly  associated  with  very 
low  density  lipoproteins  (VLDLs),  and  an  increase  in 
concentrations of apoB100 (a component of both VLDLs 
and low-density lipoproteins (LDLs)). Circulating VLDL-
triglycerides  are  significantly  associated  with  cardio-
vascular  disease,  so  this  would  indicate  increased 
cardiovascular risk associated with fructose.
Two  main  mechanisms  may  account  for  this  effect. 
First,  fructose  stimulates  hepatic  de  novo  lipogenesis, 
thus  contributing  additional  fatty  acids  for  hepatic 
triglyceride synthesis, as mentioned earlier. The amount 
of  newly  formed  fatty  acid  synthesized  from  fructose 
remains small, however. But second, fructose ingestion 
acutely decreases VLDL-triglyceride (VLDL-TG) clearance 
in  adipose  tissue,  thus  increasing  VLDL-TG  residence 
time  in  the  blood.  An  increase  in  plasma  triglyceride 
concentration  has  been  generally  observed  with 
hypercaloric, high fructose diets, that is, when fructose is 
associated  with  excess  total  energy  intake.  There  is, 
however,  evidence  that  fructose  increases  fasting 
triglyceride even when total energy intake is calculated to 
match energy requirements.
Moreover,  there  is  strong  evidence  that  24-hour 
triglyceride concentration is an independent risk factor 
for  atherosclerosis.  In  addition,  a  high  plasma  VLDL-
triglyceride  concentration  leads  to  the  generation  of 
smaller,  more  dense  LDL  particles  through  the 
cholesteryl-ester  mediated  transfer  of  lipids  between 
VLDL  and  LDL  particles.  This  process  is  further 
enhanced  in  fructose-induced  hypertriglyceridemia, 
probably because of the impaired VLDL-TG clearance, 
and hence an increased residence time of VLDL in the 
blood.  Both  fructose  and  sucrose  therefore  lead  to  an 
Figure 2. Metabolism of fructose in the liver. The majority of 
fructose in the portal vein is taken up by the liver to be converted 
into glucose, glycogen, and lactate. A small portion may be either 
oxidized within hepatocytes or converted into fatty acid, which 
will be either secreted as very low density lipoprotein-triglyceride 
(VLDL-TG) particles or stored as intrahepatocellular lipids (IHCL). 
Only a minor portion escapes liver uptake and reaches the systemic 
circulation; blood fructose concentrations therefore remain very low 
even after ingestion of a large fructose load.
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the LDL fraction, a phenotype that is clearly associated 
with an increased cardiovascular risk.
In parallel, animal experiments revealed that rodents 
on a high sucrose or high fructose diet almost invariably 
develop  obesity,  insulin  resistance  and  diabetes, 
dyslipidemia, and even occasionally high blood pressure, 
the characteristic features of metabolic syndrome, which 
also together increase the risk of cardiovascular disease. 
Furthermore, these adverse metabolic effects have been 
shown to be largely attributable to the fructose component 
of  sucrose.  One  must  recognize,  however,  that  feeding 
animals  a  high-fat  diet  leads  to  similar  metabolic 
alterations, and that energy excess from any food source 
may  be  the  critical  factor  responsible  for  metabolic 
alterations.
If high fructose intake can be responsible 
for the development of obesity and the 
associated metabolic disorders that constitute 
metabolic syndrome, wouldn’t this show up in 
epidemiological studies?
The  answer  to  this  question  is  not  straightforward. 
Several  large  cohort  studies  have  included  a  dietary 
evaluation  and  a  medical  follow-up,  but  their 
interpretation is problematic, for several reasons. First, 
until  recently,  fructose  as  such  did  not  appear  in 
nutritional databases, and these studies therefore looked 
at  a  variety  of  different  variables,  some  evaluating  the 
effects of calculated total sugar intake, others the effects 
of calculated fructose intake, while others examined the 
effects  of  specific  food  groups  (sugar-sweetened 
beverages, sweets) that contribute substantially to total 
fructose  intake.  Second,  the  results  vary  according  to 
how statistical analyses were performed. On one hand, 
some  studies  used  a  statistical  analysis  that  was  not 
adjusted  for  total  energy  intake,  and  documented  a 
positive  correlation  with  obesity.  Some  of  these  same 
studies,  however,  reported  that  obesity  was  associated 
not  only  with  sugar-sweetened  beverages  and  sweet 
intakes, but also with the consumption of potatoes and 
meat. On the other hand, some investigators argued that, 
in order to conclude that fructose (or sugar) is a major 
determinant  of  obesity,  it  is  necessary  to  establish  a 
positive correlation that is independent of total energy 
intake. These studies searched for a relationship between 
obesity  and  sugar  intake  expressed  as  a  percentage  of 
total  calorie  intake  and  generally  failed  to  observe  a 
significant  positive  correlation,  or  even  reported  a 
negative correlation. Furthermore, although these studies 
reported  that  the  incidence  of  diabetes,  dyslipidemia, 
liver  disorders,  or  high  blood  pressure  correlated 
positively with sugar intake, these relationships were no 
longer observed after adjusting for total body weight.
You say it’s hard to distinguish effects of fructose 
on obesity from effects of any excess eating – could 
fructose just be encouraging us to eat more?
Yes.  Rodents  fed  ad  libitum  a  high-sucrose  or  a  high-
fructose diet invariably increase their body weight and 
body fat mass because of an increased total energy intake. 
This may be due to a stimulation of sweet receptors in the 
mouth activating reward pathways within the brain.
Alternatively, ingestion of fructose or sucrose may elicit 
lower satiety responses than other nutrients. Satiety is a 
process through which eating sends signals that activate 
specific  brain  pathways  that  in  turn  regulate  appetite. 
Protein and carbohydrate have long been known to elicit 
a robust satiety response, mediated in part by an increase 
in  insulin.  Some  observations  suggest  that  fructose  or 
sugar exert less satiating effects than starch or glucose. 
Possibly  due  to  a  lower  insulin  response.  In  humans, 
there is evidence that a meal containing 30% energy as 
fructose, compared with a similar meal containing 30% 
glucose,  elicits  lower  postprandial  concentrations  of 
glucose, insulin and leptin, and higher concentrations of 
ghrelin in the blood. Since high blood glucose, insulin 
and  leptin  are  known  as  satiating  signals  to  the  brain, 
while ghrelin stimulates food intake, one would expect 
that fructose would indeed exert lower satiating effects 
than other carbohydrates. The significance of this has not 
been  demonstrated  in  practice,  however,  and  several 
small studies assessing the satiety induced by meals with 
various  glucose:fructose  ratios  did  not  present 
compelling evidence that fructose and sucrose are less 
satiating than other foods. A recent meta-analysis quite 
expectedly demonstrated that fructose intake leads, over 
short  periods,  to  an  increase  in  body  weight  when 
consumed as part of a high-calorie diet, but not as part of 
an  energy  balanced  diet.  This  reminds  us  that  body 
weight is strictly dependent on energy balance, and that, 
if anything, fructose would increase body weight through 
an increase in total energy intake.
Obesity  is  clearly  associated  with  metabolic  disease, 
but not all fat deposits are equal in this respect. Fat stored 
within the abdominal cavity, that is, visceral fat, is much 
more closely associated with cardiovascular diseases than 
subcutaneous  fat.  It  has  been  proposed,  based  on  one 
single study, that fructose associated with excess energy 
intake  would  preferentially  increase  visceral  fat.  This 
needs to be confirmed in larger, well controlled studies, 
however.
What about other aspects of metabolic syndrome? 
Is fructose implicated in increased fat storage in 
the liver and for the development of non-alcoholic 
fatty liver disease?
Overfeeding with 30% energy as fructose nearly doubles 
intrahepatic  fat  content  in  healthy  volunteers  within  a 
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fructose  fails  to  enhance  intrahepatic  fat  significantly, 
even when exposure is sustained for 4 weeks. Whether 
fructose  exposure  of  longer  duration  would  lead  to 
continuous,  more  important  deposition  of  intrahepatic 
fat  and  clinical  hepatic  steatosis  (fatty  liver)  remains 
presently unknown. No large epidemiological study has 
evaluated the relationship between fructose or sucrose 
intake and non-alcoholic fatty liver disease (NAFLD) so 
far, so the suspicion that fructose may be deleterious for 
liver cells rests mainly on animal experiments. There are 
indeed  observations,  in  animal  models,  that  suggest 
fructose may promote hepatic inflammation and fibrosis, 
and hence may possibly play a role in the progression of 
NAFLD to non-alcoholic steatohepatitis (NASH).
And insulin resistance, could high fructose intake 
be a cause of this?
Insulin  concentration  increases  after  a  meal,  and  is 
instrumental in maintaining adequate glucose concentra-
tions. It works by stimulating glucose uptake in skeletal 
muscle and adipose cells, increasing glucose oxidation to 
generate  energy  in  the  form  of  ATP,  and  favoring  the 
storage of lipids in adipose tissue. In many obese subjects, 
and  more  particularly  so  in  subjects  with  abdominal 
obesity, these effects of insulin are blunted, resulting in 
post-prandial hyperglycemia and hyper  lipemia in spite of 
a  normal  or  even  increased  insulin  secretion.  This 
alteration of insulin’s effect, known as insulin resistance, 
is a major factor responsible for hyper  glycemia in type 2 
diabetes mellitus, and a prominent feature of metabolic 
syndrome. The mechanisms remain incompletely under-
stood, but accumulation of tri  glyceride inside hepatocytes 
and  muscle  fibers,  generating  toxic  intracellular  lipid 
metabolites, is known to be involved.
In rodents fed high fructose diets, hyperglycemia and 
insulin resistance develop, but occur concomitantly with 
obesity, and hence the effects of fructose per se and those 
linked  to  excess  body  fat  mass  cannot  be  easily 
distinguished.  There  is  evidence,  however,  that  hepatic 
insulin  resistance,  characterized  by  increased  fasting 
glucose production and impaired postprandial suppression 
of glucose output, occurs early after exposure to fructose, 
before important changes in body composition occur.
In  humans,  short-term  overfeeding  with  20  to  30% 
extra  energy  provided  as  fructose  leads  to  a  slight 
increase  in  fasting  plasma  glucose,  and  to  a  moderate 
(approximately  10%)  increase  in  fasting  glucose 
production,  indicating  some  impairment  of  hepatic 
insulin  sensitivity.  These  changes  occur  rapidly,  within 
the first week after fructose exposure. There is, however, 
no detectable decrease in glucose disposal rate induced 
by  insulin  when  measured  by  euglycemic 
hyperinsulinemic clamps (the most reliable method for 
measuring  insulin  resistance),  indicating  no  significant 
whole  body  insulin  resistance.  In  overweight  subjects, 
fructose overfeeding for 10 weeks led to a modest 1 to 
3 kg  body  weight  gain  and  significantly  increased 
postprandial  blood  glucose  and  insulin  concentrations, 
but  the  average  blood  glucose  concentration  barely 
reached  the  2-hour  postprandial  value  of  140  mg/dl, 
which  corresponds  to  an  impaired  glucose  tolerance. 
Based  on  the  absence  of  directly  documented  insulin 
resistance,  and  the  modest  changes  in  glycemia  and 
insulinemia observed even after very high fructose intake 
over  several  weeks,  it  appears  that  fructose  per  se  is 
unlikely  to  be  responsible  for  important  alterations  of 
glucose homeostasis.
One  cannot,  however,  discard  the  hypothesis  that 
longer exposure to high fructose intake may be associated 
with insulin resistance, possibly secondary to increased 
body fat mass. In addition, a number of mechanisms that 
could  theoretically  lead  to  insulin  resistance  have 
emerged from animal or in vitro experiments. Specifically, 
fructose  has  been  shown  to  cause  uric  acid-mediated 
inhibition  of  endothelium-dependant  vasodilation,  to 
impair insulin signaling secondary to oxidative stress, to 
stimulate  hepatic  and  extra-hepatic  inflammation  and 
fibrosis,  and  to  induce  lipotoxicity  in  skeletal  muscle 
(Figure 3). Further studies will be required to evaluate 
whether these mechanisms may be responsible for the 
development of insulin resistance in humans with years-
long exposure to fructose.
How much fructose do you have to consume to see 
adverse effects?
One recent meta-analysis of several small trials in healthy 
volunteers  indicated  that  fasting  and  postprandial 
triglyceride  concentrations  were  increased  with  intake 
higher than 100 g and 50 g/day, respectively (corresponding 
to sucrose intake of 200 and 100 g/day). In an average 
non-obese  individual  with  moderate  physical  activity, 
this corresponds to 15 to 20% and 7.5 to 10%, respectively, 
of  total  daily  energy  intake.  Another  meta-analysis  of 
studies in which fructose was substituted for starch in the 
diet  of  type  2  diabetic  subjects  indicated  that  plasma 
triglyceride  concentrations  were  increased  for  fructose 
intakes higher than 60 g/day. However, even with moderate 
amounts of fructose (40 g/day) that do not change fasting 
plasma triglycerides, one can observe a shift from large to 
more atherogenic small, dense LDL particles.
Is the average consumption of sugar worldwide 
dangerous?
Consumption  of  sugar  is  about  100  to  150  g/day  in 
America, Europe, and Oceania (with important regional 
differences), corresponding to 50 to 75 g of fructose daily. 
Since  these  are  averages  for  the  whole  population,  it 
Tappy BMC Biology 2012, 10:42 
http://www.biomedcentral.com/1741-7007/10/42
Page 5 of 7means that probably about half of the population has a 
daily  consumption  in  excess  of  these  figures,  and  may 
thus  be  possibly  exposed  to  fructose-induced 
dyslipidemia.  In  the  USA,  the  average  consumption  of 
fructose,  calculated  from  the  National  Health  and 
Nutritional Examination Survey III data, was 55 g/day for 
the  whole  population.  In  adults,  however,  10%  of  the 
population was consuming more than 15% of their daily 
energy intake as fructose. Thus, while the major portion 
of the population may have innocuous fructose intake, a 
small but still significant portion of the population may 
be exposed to high, potentially deleterious intakes.
Is everybody at the same risk of developing 
dyslipidemia and metabolic diseases from a high 
fructose intake?
This important question remains unanswered at present, 
though there are indications that the answer will be ‘no’. It 
is well known that athletes and individuals involved in 
strenuous  physical  activity  often  have  high  sugar 
consumption,  but  as  a  group  have  less  metabolic  and 
cardiovascular disease than sedentary subjects. A recent 
study conducted by my laboratory finds that with daily 
exercise,  high  fructose  consumption  does  not  increase 
plasma  triglyceride  concentration.  Short-term  fructose 
overfeeding has been shown to cause less dyslipidemia in 
pre-menopausal women than in men (and no change in 
hepatic insulin sensitivity). Physical activity, gender, and 
possibly ethnic or genetic factors may therefore modulate 
the health effects of fructose. For athletes, a high fructose 
intake may even be beneficial, as it has been shown that 
fructose can be metabolized during exercise, and increase 
performance.
How might that work?
Athletes frequently use foods and drinks rich in rapidly 
absorbed  carbohydrate  during  exercise  to  provide  a 
continuous  energy  substrate  to  the  working  muscle. 
Lactic acid produced from fructose can be oxidized by 
the  working  muscle,  and  hence  moderate  amounts  of 
fructose consumed together with glucose during exercise 
can  increase  total  carbohydrate  oxidation  and  may 
improve physical performance. Since fructose is known 
to  cause  a  larger  synthesis  of  hepatic  glycogen  than 
glucose, its presence in the diet before and after exercise 
may also be beneficial to ensure high hepatic glycogen 
stores.
On the available evidence, is it time for public 
health action?
That  question  cannot  be  definitively  answered  on  the 
basis  of  the  available  evidence.  A  high  fructose  diet, 
consumed by sedentary individuals, consistently increases 
hepatic  VLDL-TG  secretion  through  stimulation  of  de 
novo lipogenesis in the liver and decreased extrahepatic 
VLDL-TG clearance. It also alters LDL particle size, thus 
leading  to  alterations  of  the  lipid  profile  known  to  be 
associated with increased cardiovascular diseases. These 
alterations are, however, observed only at very high levels 
of  fructose  intake.  In  contrast,  even  at  high  doses, 
fructose  produces  only  modest  alterations  of  glucose 
homeostasis. Fructose indisputably alters hepatic glucose 
production,  but  with  little  impact  on  blood  glucose 
concentrations,  and  does  not  alter  whole  body  insulin 
sensitivity independently of body weight changes.
But major questions remain to be addressed before we 
have  a  clear  idea  of  the  role  of  fructose  in  metabolic 
diseases.
So what do we still need to know?
First, it is not clear whether fructose consumption leads 
to increased total energy intake and obesity. To address 
this question further studies focusing on the effects of 
fructose on food intake control will be needed, and the 
possibility  that  fructose  may  increase  energy  intake 
through mechanisms related to addiction will need to be 
assessed. We also need to assess whether interventions 
aimed at reducing fructose intake in overweight subjects, 
Figure 3. Putative mechanisms that may link excessive fructose 
intake to the development of metabolic disorders in the long 
term. Stimulation of hepatic de novo lipogenesis may lead to the 
deposition of fat within the liver, which may secondarily be involved 
in hepatic insulin resistance. Hepatic de novo lipogenesis may also 
cause an increase in VLDL-TG secretion and ectopic deposition of 
lipids in skeletal muscle, and contribute to muscle insulin resistance 
through the generation of muscle lipid metabolites. Fructose 
metabolism in the liver increases uric acid synthesis, and the ensuing 
hyperuricemia can secondarily be responsible for endothelial cell 
dysfunction, impaired insulin-induced vasodilation and a consequent 
failure to increase muscle blood flow after a meal, leading to muscle 
insulin resistance. In addition, the metabolism of fructose in liver cells 
can cause the formation of reactive oxygen species (ROS), which 
can activate nuclear factor (NF)kB, causing inflammation-linked 
insulin resistance. Finally, fructose can increase the translocation of 
bacterial endotoxin (lipopolysaccharide (LPS)) into the portal blood, 
causing endotoxin-mediated stimulation of inflammation. TNF, tumor 
necrosis factor.
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and  cardiovascular  and  metabolic  risk  factors.  Such 
studies  are  obviously  needed  before  implementing 
litigation or policies aimed at reducing consumption of 
sugars at the population level.
Second,  we  do  not  know  whether  fructose  causes 
insulin resistance and diabetes mellitus in the long term. 
Even with very high fructose supplementation, there is 
only a modest alteration of hepatic glucose metabolism, 
which may merely represent a metabolic adaptation to 
the consumption of a glycogenic substrate rather than a 
step toward diabetes. There are, however, a number of 
plausible mechanisms documented in animal studies that 
may lead to deterioration of glucose homeostasis in the 
long term. We will need more basic and clinical studies to 
better evaluate whether these data are relevant to human 
health.
Finally, we need a better understanding of the genetic 
and  environmental  factors  in  the  effect  of  fructose 
consumption.  There  is  good  evidence  that  pre-
menopausal  women  and  physically  active  males  and 
females may be resistant to the adverse metabolic effects 
of fructose, and it can by hypothesized that other sub-
groups of individuals may have enhanced responsiveness 
and would benefit from a dietary restriction. To address 
this question, we need comparative studies of fructose’s 
effects  in  populations  at  increased  risk  of  developing 
metabolic  diseases,  such  as  offspring  of  subjects  with 
type 2 diabetes, overweight individuals, insulin-resistant 
subjects,  or  ethnic  groups  with  a  high  incidence  of 
metabolic diseases.
So what can we conclude?
There is clearly cause for immediate concern regarding 
potential long-term effects of very high fructose intake in 
patients with metabolic disorders and in subjects already 
at risk of developing metabolic disease due to overweight 
or  low  physical  activity.  Given  the  substantial 
consumption  of  fructose  in  our  diet,  mainly  from 
sweetened beverages, sweet snacks, and cereal products 
with added sugar, and the fact that fructose is an entirely 
dispensable  nutrient,  it  appears  sound  to  limit 
consumption of sugar as part of any weight loss program 
and in individuals at high risk of developing metabolic 
diseases. There is no evidence, however, that fructose is 
the sole, or even the main factor in the development of 
these diseases, nor that it is deleterious to everybody, and 
public  health  initiatives  should  therefore  broadly  focus 
on  the  promotion  of  healthy  lifestyles  generally,  with 
restriction of both sugar and saturated fat intakes, and 
consumption of whole grains, fresh fruits and vegetables 
rather  than  focusing  exclusively  on  reduction  of  sugar 
intake.
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